HomeCompareMGDDY vs ABBV

MGDDY vs ABBV: Dividend Comparison 2026

MGDDY yields 4.44% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MGDDY wins by $3188.28M in total portfolio value
10 years
MGDDY
MGDDY
● Live price
4.44%
Share price
$17.01
Annual div
$0.76
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3188.39M
Annual income
$3,056,246,099.98
Full MGDDY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — MGDDY vs ABBV

📍 MGDDY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMGDDYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MGDDY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MGDDY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MGDDY
Annual income on $10K today (after 15% tax)
$377.67/yr
After 10yr DRIP, annual income (after tax)
$2,597,809,184.98/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, MGDDY beats the other by $2,597,788,128.98/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MGDDY + ABBV for your $10,000?

MGDDY: 50%ABBV: 50%
100% ABBV50/50100% MGDDY
Portfolio after 10yr
$1594.24M
Annual income
$1,528,135,435.87/yr
Blended yield
95.85%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

MGDDY
Analyst Ratings
1
Hold
Consensus: Hold
Price Target
$43.00
+152.8% upside vs current
Range: $43.00 — $43.00
Altman Z
3.6
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MGDDY buys
0
ABBV buys
0
No recent congressional trades found for MGDDY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMGDDYABBV
Forward yield4.44%3.06%
Annual dividend / share$0.76$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$3188.39M$102.3K
Annual income after 10y$3,056,246,099.98$24,771.77
Total dividends collected$3179.03M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy
Analyst price target$43.00$256.15

Year-by-year: MGDDY vs ABBV ($10,000, DRIP)

YearMGDDY PortfolioMGDDY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,589$888.63$11,550$430.00+$39.00MGDDY
2$14,325$1,924.86$13,472$627.96+$853.00MGDDY
3$19,775$4,447.32$15,906$926.08+$3.9KMGDDY
4$32,634$11,475.45$19,071$1,382.55+$13.6KMGDDY
5$70,317$35,398.20$23,302$2,095.81+$47.0KMGDDY
6$217,804$142,564.71$29,150$3,237.93+$188.7KMGDDY
7$1,058,448$825,398.07$37,536$5,121.41+$1.02MMGDDY
8$8,629,990$7,497,450.17$50,079$8,338.38+$8.58MMGDDY
9$123,495,729$114,261,639.48$69,753$14,065.80+$123.43MMGDDY
10$3,188,386,530$3,056,246,099.98$102,337$24,771.77+$3188.28MMGDDY

MGDDY vs ABBV: Complete Analysis 2026

MGDDYStock

Compagnie Générale des Établissements Michelin Société en commandite par actions manufactures and sells tires worldwide. The company offers tires for private use covering cars, racing, biking, motorcycles, scooters, and mopeds; and professional use, such as freight and people transport, agriculture, construction and industrial, mining and quarries, corporate fleets, tradesmen and professionals, civil and military operations, light rail, and aircraft. It is also involved in the provision of tire-related services, including development of mobility solutions for fleet managers, vehicle manufacturers, farmers, distributors, and individuals; mobility services, such as road maps, mobile apps, itineraries, and travel guides; lifestyle products comprising car and bike accessories, shoe soles, and sports and leisure gears; and high-tech materials that include 3D metal printing, specialty, rubber, biosourced, and recycled materials. Compagnie Générale des Établissements Michelin Société en commandite par actions was incorporated in 1863 and is based in Clermont-Ferrand, France.

Full MGDDY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this MGDDY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MGDDY vs SCHDMGDDY vs JEPIMGDDY vs OMGDDY vs KOMGDDY vs MAINMGDDY vs JNJMGDDY vs MRKMGDDY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.